Lancet publishes ACHIEVE-3 comparing oral orforglipron with oral semaglutide

The wire

1. 01The Lancet published ACHIEVE-3, a multinational, multicentre, open-label Phase 3 non-inferiority trial of once-daily oral orforglipron versus oral semaglutide in adults with type 2 diabetes.
2. 02A head-to-head oral comparison is the key data point for clinicians weighing a non-peptide small-molecule option against the existing oral GLP-1.
3. 03The trial was open-label, which can influence tolerability and adherence reporting; readers should check the published efficacy margins and adverse-event rates.

From the source

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial